# EDGAR Filing Document

**Accession Number:** 0001237831
**File Stem:** 0001193125-25-307215
**Filing Date:** 2025-12
**Character Count:** 7704
**Document Hash:** cc66b067a25496c8f2602c5f6e9d7125
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-307215.hdr.sgml**: 20251203

**ACCESSION NUMBER**: 0001193125-25-307215

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251201

**FILED AS OF DATE**: 20251203

**DATE AS OF CHANGE**: 20251203

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Kline Kyle
- **CENTRAL INDEX KEY:** 0002080625

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35621
- **FILM NUMBER:** 251547982

**MAIL ADDRESS:**
- **STREET 1:** 2560 GENERAL ARMISTEAD AVE
- **CITY:** AUDUBON
- **STATE:** PA
- **ZIP:** 19403
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GLOBUS MEDICAL INC
- **CENTRAL INDEX KEY:** 0001237831
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 043744954
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 2560 GENERAL ARMISTEAD AVENUE
- **CITY:** AUDUBON
- **STATE:** PA
- **ZIP:** 19403
- **BUSINESS PHONE:** 610-930-1800

**MAIL ADDRESS:**
- **STREET 1:** 2560 GENERAL ARMISTEAD AVENUE
- **CITY:** AUDUBON
- **STATE:** PA
- **ZIP:** 19403

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Kline Kyle<br><sub>(Last) (First) (Middle)</sub><br>VALLEY FORGE BUSINESS CENTER<br>2560 GENERAL ARMISTEAD AVENUE<br><sub>(Street)</sub><br>AUDUBON, PA 19403<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-12-01 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Senior Vice President, CFO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>GLOBUS MEDICAL INC [ GMED ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Class A Common Stock | 2025-12-01 |  | M |  | 3646 | A | $53.14 | 3646 | D |  |
| Class A Common Stock | 2025-12-01 |  | M |  | 5000 | A | $56.43 | 8646 | D |  |
| Class A Common Stock | 2025-12-01 |  | M |  | 5000 | A | $64.44 | 13646 | D |  |
| Class A Common Stock | 2025-12-01 |  | M |  | 4896 | A | $63.68 | 18542 | D |  |
| Class A Common Stock | 2025-12-01 |  | S<sup>(1)</sup> |  | 18542 | D | $90.00 | 0 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy Class A Common Stock) | $53.14 | 2025-12-01 |  | M |  |  | 3646 | <sup>(2)</sup> | 2033-03-24 | Class A Common Stock | 3646 | $0 | 1354 | D |  |
| Stock Option (Right to Buy Class A Common Stock) | $56.43 | 2025-12-01 |  | M |  |  | 5000 | <sup>(3)</sup> | 2034-02-27 | Class A Common Stock | 5000 | $0 | 10000 | D |  |
| Stock Option (Right to Buy Class A Common Stock) | $64.44 | 2025-12-01 |  | M |  |  | 5000 | <sup>(4)</sup> | 2031-01-25 | Class A Common Stock | 5000 | $0 | 0 | D |  |
| Stock Option (Right to Buy Class A Common Stock) | $63.68 | 2025-12-01 |  | M |  |  | 5000 | <sup>(5)</sup> | 2032-01-27 | Class A Common Stock | 5000 | $0 | 0 | D |  |

---

### Footnotes:

(1) This sale was effectuated pursuant to a Rule 10b5-1 trading plan dated August 25, 2025 executed by the reporting person.

(2) These options were granted on March 24, 2023, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2024, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

(3) These options were granted on February 27, 2024, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2025, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

(4) These options were granted on January 25, 2021 and are fully vested.

(5) These options were granted on January 27, 2022, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2023, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

**Signature:** /s/ Kelly G. Huller, Attorney-in-Fact  
**Date:** 2025-12-03

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**